354 related articles for article (PubMed ID: 26035328)
21. Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.
Young TP; Napolitano LA; Paquet AC; Parkin NT; Fransen S; Trinh R; Haddad M; Hackett J; Cloherty GA
J Virol Methods; 2013 Nov; 193(2):693-6. PubMed ID: 23892128
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.
Reigadas S; Marcelin AG; Houssaïni A; Yerly S; Descamps D; Plantier JC; Ruffault A; Amiel C; Trabaud MA; Flandre P; Fleury H; Masquelier B;
J Antimicrob Chemother; 2013 Apr; 68(4):969-72. PubMed ID: 23184711
[No Abstract] [Full Text] [Related]
23. Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay.
Péré H; Roques P; Talla F; Meillo H; Charpentier C; Bélec L
AIDS; 2015 Jun; 29(10):1267-9. PubMed ID: 26035326
[No Abstract] [Full Text] [Related]
24. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
[TBL] [Abstract][Full Text] [Related]
25. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.
Santos JR; Blanco JL; Masiá M; Gutiérrez F; Pérez-Elías MJ; Iribarren JA; Force L; Antela A; Knobel H; Salavert M; López Bernaldo De Quirós JC; Pino M; Paredes R; Clotet B; ;
J Antimicrob Chemother; 2015 Nov; 70(11):3087-95. PubMed ID: 26490727
[TBL] [Abstract][Full Text] [Related]
26. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
[TBL] [Abstract][Full Text] [Related]
27. Integrase Resistance-Associated Mutations on Raltegravir Failure in Western India: A Preliminary Analysis.
Pujari SN; Gaikwad S; Joshi K; Dabhade D; Sane S; Rao NP; Bele V
J Acquir Immune Defic Syndr; 2018 Apr; 77(5):e42-e45. PubMed ID: 29315113
[No Abstract] [Full Text] [Related]
28. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
[TBL] [Abstract][Full Text] [Related]
29. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
[TBL] [Abstract][Full Text] [Related]
30. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
31. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
32. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
[No Abstract] [Full Text] [Related]
33. Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.
Mantovani NP; Azevedo RG; Rabelato JT; Sanabani S; Diaz RS; Komninakis SV
J Clin Microbiol; 2012 Jun; 50(6):2122-5. PubMed ID: 22403424
[TBL] [Abstract][Full Text] [Related]
34. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral therapy for HIV: drug resistance and sequencing.
Burkle WS
J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862
[No Abstract] [Full Text] [Related]
36. Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
Crawford KW
AIDS; 2014 Sep; 28(15):2331-2. PubMed ID: 25050862
[No Abstract] [Full Text] [Related]
37. HIV-1 integrase inhibitor resistance and its clinical implications.
Blanco JL; Varghese V; Rhee SY; Gatell JM; Shafer RW
J Infect Dis; 2011 May; 203(9):1204-14. PubMed ID: 21459813
[TBL] [Abstract][Full Text] [Related]
38. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
[TBL] [Abstract][Full Text] [Related]
39. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
Bannister WP; Cozzi-Lepri A; Kjær J; Clotet B; Lazzarin A; Viard JP; Kronborg G; Duiculescu D; Beniowski M; Machala L; Phillips A;
J Antimicrob Chemother; 2011 Apr; 66(4):901-11. PubMed ID: 21393179
[TBL] [Abstract][Full Text] [Related]
40. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
